This process translates into a decreased sensitivity of ER+ breast cancer cells to endocrine therapy, which involves an enhancer of zeste homolog 2 (EZH2)-mediated reprogramming that also seems to induce stemness in breast cancer bone metastasis (37). The gene discussed is EZH2; the disease is breast cancer.